Key result
Acetylsalicylic acid plus dipyridamole reduced the incidence of death from all causes or strokes by 33.5% (p<0.001) compared to placebo in patients with previous cerebrovascular disorders.
Why the study?
Does acetylsalicylic acid plus dipyridamole reduce deaths from all causes or strokes in patients with previous cerebrovascular disorders?
Population
2,500 patients with previous cerebrovascular disorders
Comparison
Acetylsalicylic acid plus dipyridamole vs Matched placebo
Design
RCT
Follow-up
2 years
Loading...
May support dual antiplatelet therapy post-stroke; leaves open confirmation in contemporary randomized trials.
RCT (n=2,500)
Does acetylsalicylic acid plus dipyridamole reduce deaths from all causes or strokes in patients with previous cerebrovascular disorders?
Effect estimate: 33.5% reduction
p-value: p=<0.001
Combination therapy with acetylsalicylic acid and dipyridamole significantly reduces the risk of death or stroke in patients with prior cerebrovascular events compared to placebo.
A 1990 study conducted an RCT in previous cerebrovascular disorders (n=2,500). acetylsalicylic acid plus dipyridamole vs. matched placebo was evaluated on deaths from all causes or strokes (33.5% reduction, p=<0.001). Acetylsalicylic acid plus dipyridamole reduced the incidence of death from all causes or strokes by 33.5% (p<0.001) compared to placebo in patients with previous cerebrovascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: